The hospital received a five-year $5 million grant from CDC to survey for communicable diseases in children and evaluate vaccine effectiveness.
The Children’s Hospital of Pittsburgh of UPMC announced on Sept. 29, 2016 that it has received a $5 million, five-year, grant from the United States Centers for Disease Control and Prevention (CDC) to join the New Vaccine Surveillance Network (NVSN). The hospital joins a group of medical centers nationwide that survey for communicable disease in children and evaluate vaccine effectiveness.
“There are few or no effective antivirals for these viruses, and therefore vaccination is the most promising intervention,” John V. Williams, MD, chief, Division of Infectious Diseases at Children’s and principal investigator of the new NVSN site said in a statement. “Active disease surveillance is necessary to establish the effectiveness of existing vaccines and provide the data needed to guide policymakers and pharmaceutical industries in the development of new vaccines. We intend to provide that critical information.”
The children’s hospital site of the NVSN has three aims:
The NVSN has been funded by the CDC since 2000, becoming a core component of national influenza surveillance. The University of Pittsburgh’s Vaccination Research Group provides additional information on a broader, primarily adult population of people seen at UPMC outpatient facilities for potential influenza.
Source: Children’s Hospital of Pittsburgh
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.